10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
10x Genomics (TXG) has secured a significant legal victory against Parse Biosciences through a consent agreement entered on February 25, 2025, in the U.S. District Court for the District of Delaware. Parse agreed to a worldwide permanent injunction preventing them from making, using, or selling their planned ATAC and ATAC-Multiome Single Cell products.
Parse has admitted that 10x's ATAC-seq patents are valid, enforceable, and infringed by Parse's use of ATAC-seq methods and compositions. The agreement was reached one week before the scheduled trial. While this resolves the ATAC-related dispute, litigation regarding Parse's gene expression products continues, with additional patents under appeal. The March 2025 trial for remaining patent infringement claims has been stayed pending these appeals.
10x Genomics (TXG) ha ottenuto una significativa vittoria legale contro Parse Biosciences attraverso un accordo di consenso stipulato il 25 febbraio 2025, presso il Tribunale Distrettuale degli Stati Uniti per il Distretto del Delaware. Parse ha accettato un divieto permanente a livello mondiale che impedisce loro di produrre, utilizzare o vendere i loro prodotti ATAC e ATAC-Multiome Single Cell pianificati.
Parse ha ammesso che i brevetti ATAC-seq di 10x sono validi, applicabili e violati dall'uso da parte di Parse dei metodi e delle composizioni ATAC-seq. L'accordo è stato raggiunto una settimana prima del processo programmato. Sebbene questo risolva la controversia relativa all'ATAC, la contesa riguardante i prodotti di espressione genica di Parse continua, con ulteriori brevetti in fase di appello. Il processo di marzo 2025 per le restanti rivendicazioni di violazione di brevetto è stato sospeso in attesa di questi appelli.
10x Genomics (TXG) ha logrado una victoria legal significativa contra Parse Biosciences a través de un acuerdo de consentimiento firmado el 25 de febrero de 2025, en el Tribunal de Distrito de EE. UU. para el Distrito de Delaware. Parse aceptó un injunction permanente a nivel mundial que les impide fabricar, usar o vender sus productos planeados ATAC y ATAC-Multiome Single Cell.
Parse ha admitido que los patentes ATAC-seq de 10x son válidos, aplicables y infringidos por el uso de métodos y composiciones ATAC-seq por parte de Parse. El acuerdo se alcanzó una semana antes del juicio programado. Si bien esto resuelve la disputa relacionada con ATAC, la litigación sobre los productos de expresión génica de Parse continúa, con patentes adicionales en apelación. El juicio de marzo de 2025 para las reclamaciones de infracción de patente restantes ha sido suspendido a la espera de estas apelaciones.
10x Genomics (TXG)는 2025년 2월 25일 델라웨어 지방법원에서 체결된 합의 계약을 통해 Parse Biosciences에 대해 중요한 법적 승리를 거두었습니다. Parse는 전 세계적으로 영구적인 금지명령에 동의하여 그들이 계획한 ATAC 및 ATAC-Multiome Single Cell 제품을 제조, 사용 또는 판매하는 것을 금지합니다.
Parse는 10x의 ATAC-seq 특허가 유효하고 집행 가능하며 Parse의 ATAC-seq 방법 및 조성을 사용함으로써 침해되었다고 인정했습니다. 이 합의는 예정된 재판 일주일 전에 도달했습니다. 이는 ATAC 관련 분쟁을 해결하지만, Parse의 유전자 발현 제품에 대한 소송은 계속 진행 중이며, 추가 특허가 항소 중입니다. 남은 특허 침해 주장에 대한 2025년 3월 재판은 이러한 항소가 진행되는 동안 중단되었습니다.
10x Genomics (TXG) a remporté une victoire juridique significative contre Parse Biosciences grâce à un accord de consentement conclu le 25 février 2025, devant le tribunal de district des États-Unis pour le district du Delaware. Parse a accepté une interdiction permanente mondiale les empêchant de fabriquer, d'utiliser ou de vendre leurs produits ATAC et ATAC-Multiome Single Cell prévus.
Parse a admis que les brevets ATAC-seq de 10x sont valides, applicables et enfreints par l'utilisation par Parse des méthodes et compositions ATAC-seq. L'accord a été conclu une semaine avant le procès prévu. Bien que cela résolve le différend lié à l'ATAC, le contentieux concernant les produits d'expression génique de Parse se poursuit, avec des brevets supplémentaires en appel. Le procès de mars 2025 concernant les réclamations restantes pour violation de brevet a été suspendu en attendant ces appels.
10x Genomics (TXG) hat einen bedeutenden rechtlichen Sieg gegen Parse Biosciences durch eine am 25. Februar 2025 geschlossene Zustimmungserklärung vor dem US-Bezirksgericht für den Bezirk Delaware erzielt. Parse stimmte einer weltweiten dauerhaften Unterlassungsverfügung zu, die es ihnen untersagt, ihre geplanten ATAC- und ATAC-Multiome Single Cell-Produkte herzustellen, zu verwenden oder zu verkaufen.
Parse hat zugegeben, dass die ATAC-seq-Patente von 10x gültig, durchsetzbar und von Parse durch die Verwendung von ATAC-seq-Methoden und -Zusammensetzungen verletzt werden. Die Vereinbarung wurde eine Woche vor dem geplanten Prozess erzielt. Während dies den ATAC-bezogenen Streit beilegt, geht der Rechtsstreit über Parse's Genexpressionsprodukte weiter, mit weiteren Patenten, die in Berufung sind. Der Prozess im März 2025 für die verbleibenden Patentverletzungsansprüche wurde ausgesetzt, bis diese Berufungen entschieden sind.
- Secured worldwide permanent injunction against competitor Parse Biosciences
- Competitor admitted 10x's ATAC-seq patents are valid and enforceable
- Strengthened market position in ATAC and ATAC-Multiome Single Cell products segment
- Ongoing litigation costs with Parse over gene expression products
- Additional patent disputes remain under appeal
10x Genomics' ATAC-Seq patents found valid and infringed
"This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal."
The company's litigation against Parse's gene expression products remains ongoing, with additional asserted patents under appeal. Following entry of the injunction, the trial scheduled for March 2025 concerning 10x's remaining patent infringement claims against Parse has been stayed pending those appeals.
10x Genomics is committed to defending its intellectual property and investing in groundbreaking technologies that empower researchers worldwide.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and potential outcomes of litigation. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-secures-injunction-against-parse-biosciences-planned-atac-products-302390537.html
SOURCE 10x Genomics, Inc
FAQ
What is the outcome of 10x Genomics' patent litigation against Parse Biosciences?
How does the Parse Biosciences injunction affect TXG's market position?
What pending legal issues remain between 10x Genomics and Parse Biosciences?
When was the Parse Biosciences consent agreement reached?
